#United States #Los Angeles #Biocodex #Stiripentol #Dravet Syndrome

Biocodex to Present New Data at AES 2024

Biocodex, a global player in the pharmaceutical sector with a strong commitment to tackling rare pediatric diseases, is set to reveal seven pivotal studies during the upcoming American Epilepsy Society (AES) 2024 Annual Meeting in Los Angeles, California. Scheduled from December 6-10, this meeting will shine a spotlight on the findings surrounding stiripentol, which is used particularly in the treatment of Dravet syndrome, a severe form of epilepsy.

Focus on Dravet Syndrome

Dravet syndrome is a genetic disorder characterized by frequent, prolonged seizures that begin within the first year of life. A significant challenge in pediatric healthcare, this condition not only affects the quality of life for these young patients but also places immense burdens on their families. Studies conducted by Biocodex will address various aspects of treatment protocols and patient outcomes associated with stiripentol, marketed under the name DIACOMIT.

Dr. Carla Schad, the North American Medical Officer of Biocodex, expressed excitement about the upcoming presentations, emphasizing the company’s dedication to advancing research and enhancing care for patients. "We are committed to sharing vital data with healthcare providers and advocates, aiming to prioritize patient needs in every aspect of our work," Dr. Schad noted.

Presentation Highlights

The studies to be presented will cover a range of topics, including:

• - Best Practices for Initial Diagnosis: Insights from an international Delphi consensus will focus on improving communication with caregivers when delivering a Dravet syndrome diagnosis. This poster session is scheduled for December 7 from noon to 2 PM.
• - Efficacy Analysis: A retrospective study evaluating stiripentol’s effectiveness will be showcased on the same day, addressing both Dravet and non-Dravet patient records to underline its therapeutic potential.
• - Real-World Utilization: Another critical study will provide a holistic overview of stiripentol prescriptions by U.S. healthcare providers, shedding light on practical dosing strategies based on patient needs and clinical practices.

Also on the agenda is a presentation titled, "Results of the DIAVEY Study," which deals with post-marketing safety assessments of stiripentol in a European context, scheduled for December 9.

Symposia and Education Initiatives

In addition to research presentations, Biocodex will be hosting two symposia during the AES meeting. The first, led by Dr. Katherine Nickels, will address effective communication strategies when informing caregivers about Dravet syndrome. The second symposium, featuring Dr. James W. Wheless, will delve into treatment optimization for patients suffering from this complex disorder.

Additionally, Biocodex is sponsoring a Continuing Medical Education (CME) program titled, "Mortality Risk with Dravet Syndrome – Let’s Check That Box." This session is designed to educate healthcare professionals about early diagnosis, mortality risks associated with Dravet syndrome, and the potential benefits of targeted therapies.

The Importance of Stiripentol

Stiripentol (DIACOMIT) is a vital treatment option for children aged 6 months and older suffering from Dravet syndrome who are also on clobazam therapy. This compound has shown significant benefits in managing seizure frequency in patients with this challenging condition. However, it is essential to monitor patients closely for potential side effects, such as somnolence, decreased appetite, and significant changes in blood counts.

The Biocodex team remains steadfast in their mission to enhance the understanding of Dravet syndrome and improve therapeutic outcomes for affected patients.

As the company prepares to unveil its latest findings at AES 2024, it reiterates its commitment to patient-centered research and the ongoing collaboration with healthcare professionals and advocates.

To explore more about Biocodex and DIACOMIT, visit their official websites. Together, they aim to revolutionize the treatment landscape for patients with Dravet syndrome, ensuring better lives for families facing this daunting challenge.